Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Cash & Equivalents (2016 - 2026)

Pediatrix Medical (MD) has disclosed Cash & Equivalents for 17 consecutive years, with $375.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 63.19% to $375.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $375.2 million through Dec 2025, up 63.19% year-over-year, with the annual reading at $375.2 million for FY2025, 63.19% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $375.2 million at Pediatrix Medical, up from $340.1 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $387.4 million in Q4 2021, with the low at $5.8 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $145.0 million, with a median of $86.1 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents crashed 97.58% in 2022, then soared 1137.53% in 2025.
  • Over 5 years, Cash & Equivalents stood at $387.4 million in 2021, then tumbled by 97.46% to $9.8 million in 2022, then soared by 645.7% to $73.3 million in 2023, then skyrocketed by 213.88% to $229.9 million in 2024, then surged by 63.19% to $375.2 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $375.2 million, $340.1 million, and $224.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.